Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Reassessing free light chain criteria used in the diagnosis of MM

Malin Hultcrantz • 14 Jun 2022
EHA 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

In this study, Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights a study which investigated the free light chain criteria used in the 2014 IMWG diagnostic criteria, and implications of this study in the future treatment of multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research Funding: GSK, Amgen, Daiichi Sankyo, Cosette
Advisory board: BMS
Consultancy: Curio Science LLC, Intellisphere LLC
Membership on an entity’s Board of Directors or advisory committees: GSK

More from Malin Hultcrantz

0:32
The role of immunotherapy in smoldering myeloma
Malin Hultcrantz • 10 Dec 2023
0:53
Should patients with smoldering myeloma be treated outside of the clinical trial setting?
Malin Hultcrantz • 10 Dec 2023
2:26
Serum biomarkers as predictors of disease progression in smoldering myeloma
Malin Hultcrantz • 10 Dec 2023
1:38
Real-world safety and efficacy of belantamab mafodotin in R/R myeloma
Malin Hultcrantz • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals